The premise of this application is the following: Understanding the fundamental mechanisms that control the switching of globin gene expression during development and maintain silencing of fetal hemoglobin (HbF) in the adult is essential as a foundation on which to design targeted therapy for the major hemoglobin disorders-- sickle cell anemia and -thalassemia. Recent findings establish BCL11A as a major transcriptional repressor that restricts mouse embryonic -like globin expression to the primitive erythroid lineage and silences human -globin expression in mice (harboring a transgene with the entire human -globin locus). Pan-hematopoietic or erythroid-specific inactivation of BCL11A alone leads to substantial reactivation of HbF expression, and prevents disease in humanized, genetically engineered mice with sickle cell disease (SCD). Thus, the aims of the current application focus specifically on how BCL11A functions to regulate globin switches, as an improved understanding will provide critical insights into potential strategies to target down-regulation or inhibition of BCL11A expression or function to reactivate ?-globin expression in patients with the major hemoglobin disorders. In order to move forward in the discovery of small molecules that impair the function of BCL11A or its critical partner proteins, we believe it is necessary to define in depth the manner in which BCL11A functions in globin repression by delineating its principal functional domains. To this end, we will employ a BCL11A null adult erythroid mouse erythroleukemia cell line created by genome engineering to determine the domains of the protein necessary for globin repression. Second, we will determine how these domains interact with other proteins; participate in protein multimerization, and/or DNA binding. In parallel, we will explore the potential to humanize mice to express BCL11A in a human rather than a mouse pattern in development in an effort to generate an improved animal model for globin gene switching. A model of this nature would facilitate testing of gene manipulations and small molecules that reactivate HbF, and ultimately contribute to the development of new therapeutics for the major hemoglobin disorders.

Public Health Relevance

Red blood cells produce hemoglobin, the major oxygen carrying protein in our body. Inherited disorders that affect either the synthesis or structure of adult hemoglobin, the -thalassemias and sickle cell anemia, respectively, are among the most common diseases worldwide. Our work is directed toward understanding how the red blood cell is programmed to express different types of hemoglobin at different times of development. Reactivation of a fetal form of hemoglobin (HbF) greatly ameliorates the consequences of the hemoglobin diseases. The work proposed in this application directly addresses how HbF is normally silenced in development by a specific protein known as BCL11A. This protein serves as the critical molecular switch in this process. By understanding how BCL11A accomplishes its task, we will be in a favorable position to develop specific inhibitors as new therapeutics for reactivating HbF in patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL032259-33
Application #
8923328
Study Section
Molecular and Cellular Hematology Study Section (MCH)
Program Officer
Qasba, Pankaj
Project Start
1982-04-01
Project End
2018-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
33
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
Liu, Nan; Hargreaves, Victoria V; Zhu, Qian et al. (2018) Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. Cell 173:430-442.e17
Canver, Matthew C; Lessard, Samuel; Pinello, Luca et al. (2017) Variant-aware saturating mutagenesis using multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. Nat Genet 49:625-634
Masuda, Takeshi; Wang, Xin; Maeda, Manami et al. (2016) Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science 351:285-9
Canver, Matthew C; Orkin, Stuart H (2016) Customizing the genome as therapy for the ?-hemoglobinopathies. Blood 127:2536-45
Huang, Jialiang; Liu, Xin; Li, Dan et al. (2016) Dynamic Control of Enhancer Repertoires Drives Lineage and Stage-Specific Transcription during Hematopoiesis. Dev Cell 36:9-23
Hoban, Megan D; Orkin, Stuart H; Bauer, Daniel E (2016) Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood 127:839-48
Smith, Elenoe C; Orkin, Stuart H (2016) Hemoglobin genetics: recent contributions of GWAS and gene editing. Hum Mol Genet 25:R99-R105
Pinello, Luca; Canver, Matthew C; Hoban, Megan D et al. (2016) Analyzing CRISPR genome-editing experiments with CRISPResso. Nat Biotechnol 34:695-7
Luc, Sidinh; Huang, Jialiang; McEldoon, Jennifer L et al. (2016) Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype. Cell Rep 16:3181-3194
Orkin, Stuart H (2016) Recent advances in globin research using genome-wide association studies and gene editing. Ann N Y Acad Sci 1368:5-10

Showing the most recent 10 out of 53 publications